Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...
There's a lot of hope for ivonescimab, but are investors being a bit too bullish?
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Summit Therapeutics is a clinical-stage biotech company that has returned over 1,100% in 2024. Is the stock still a good buy right now?
This drugmaker faces a key test in the next several years.
At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...
/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...
Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been...
The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...
Merck’s MRK stock declined 2% on Monday after Summit Therapeutics’ SMMT investigational bispecific antibody, ivonescimab, outperformed Merck’s blockbuster PD-L1 inhibitor Keytruda in a first-line...